Cargando…

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry

INTRODUCTION: Data on the characteristics of apremilast patients in real-world settings are limited. We assessed the demographics and disease characteristics of apremilast-treated patients in the Corrona Psoriasis Registry overall and by treatment history. METHODS: The Corrona Psoriasis Registry is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gottlieb, Alice B., Merola, Joseph F., Cirulli, Joshua, Williams, Catherine C., Linowski, Gregory J., Paris, Maria, Litman, Heather J., Guo, Ning, Emeanuru, Kelechi, McLean, Robert R., Cronin, Angel, Strober, Bruce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858993/ https://www.ncbi.nlm.nih.gov/pubmed/33475970 http://dx.doi.org/10.1007/s13555-020-00479-4

Ejemplares similares

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021)

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry
por: Mease, P.J., et al.
Publicado: (2019)

Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists
por: Strober, Bruce, et al.
Publicado: (2021)

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry
por: Strober, Bruce, et al.
Publicado: (2019)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Pediatric psoriasis treated with apremilast
por: Smith, Rebecca L.
Publicado: (2016)

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Recurrence of Melanoma after Starting Apremilast for Psoriasis
por: Salopek, Thomas G.
Publicado: (2017)

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
por: Walsh, Jessica A., et al.
Publicado: (2021)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Recurrent generalized pustular psoriasis possibly triggered by apremilast
por: Wang, Wen-Ming, et al.
Publicado: (2020)

A case of erythrodermic psoriasis successfully treated with apremilast
por: Megna, Matteo, et al.
Publicado: (2021)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
por: Reich, K., et al.
Publicado: (2018)

Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis
por: Graier, Thomas, et al.
Publicado: (2020)

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
por: Afra, T. P., et al.
Publicado: (2019)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan, Murlidhar, et al.
Publicado: (2021)

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
por: Van Voorhees, A.S., et al.
Publicado: (2021)

Apremilast in People Living with HIV with Psoriasis Vulgaris: A Case Report
por: Shah, Bela J, et al.
Publicado: (2019)

Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2020)

Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink
por: Persson, Rebecca, et al.
Publicado: (2022)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
por: Palfreeman, Andrew C, et al.
Publicado: (2013)

Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis
por: Tanaka, Masayuki, et al.
Publicado: (2021)

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
por: Mayor Ibarguren, Ander, et al.
Publicado: (2021)

Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study
por: MALARA, Giovanna, et al.
Publicado: (2021)

Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
por: Ikumi, Kyoko, et al.
Publicado: (2021)

Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies
por: Liu, Yashu, et al.
Publicado: (2022)

Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris
por: Morita, Akimichi, et al.
Publicado: (2022)

Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series
por: Ständer, Sascha, et al.
Publicado: (2020)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities
por: Jeon, Caleb, et al.
Publicado: (2017)

Efficacy of Apremilast Gels in Mouse Model of Imiquimod-Induced Psoriasis Skin Inflammation
por: Silva-Abreu, Marcelle, et al.
Publicado: (2023)

Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience
por: De, Abhishek, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gdcqokp9nrslt1mgvcamircgsm